To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: Israel Approves Tobi, Antibiotic For Lung Infections URL: http://www.pslgroup.com/dg/155292.htm Doctor's Guide January 5, 2000
SEATTLE, WA -- January 5, 2000 -- PathoGenesis Corp. today announced that its drug Tobi(R) (tobramycin solution for inhalation) has received marketing clearance from the Ministry of Health in Israel. The drug is indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa lung infections. "We're delighted to add Israel to our growing list of international markets," said Wilbur H. Gantz, chairman and chief executive officer of PathoGenesis. "Tobi is an important addition to the physicians' arsenal of drugs to manage serious lung infections in their cystic fibrosis patients." In Israel, Tobi will be distributed by Teva Pharmaceutical Industries Ltd. An estimated 400 people in Israel have cystic fibrosis, a serious genetic disease that primarily affects Caucasians. Tobi is designed for these patients to take at home in repeated cycles of 28 days on drug, 28 days off drug. It is inhaled twice daily and requires about 15 minutes each time. Related Links: Tobi (tobramycin), PathoGenesis Corp. and Teva Pharmaceutical Industries Ltd. --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.